Nuove Opzioni in Pazienti Già Trattati con Cancro Del Colon Metastatico: I Sali Del Platino

Heidelberger C. , Chaudhuri N.K. , Danenberg P. : Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature, 179: 663, 1957.

Bajetta E. , Colleoni M. , Rosso R. , Sobrero A. , Amadori D. , Cornelia G. , Marangolo M. , Scanni A. , Lorusso V. , Calabresi F. : Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur. J. Cancer, 29A, 1658–1663, 1993.

Rosso R. , Mazzei T. , Sobrero A. , Mini E. , Cartei G. , Conte P. , Labianca R. , Cartei F. , Falcone A. , Pancera G. : Phase II trial of 5-fluorouracil and the natural 1 isomer of folinic acid in the treatment of advanced colorectal carcinoma. Eur. J. Cancer, 30: 338–343, 1994.

Ortiz J. , Woolley P.V. : A study of the synergistic cytotoxic effects of 5-fluorouracil and cisplatin against colon carcinoma cells using median effect analysis. Proc. Am. Assoc. Cancer Res., 28: 414, 1987.

Beaupain R. , Dionet C. : Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and x-rays on growth of human cancer nodules maintained in continuous organotypic culture. Cancer Res., 45: 3150, 1985.

Schabel F.M. Jr. , Trader M.W. , Laster W.R. Jr. , Corbett T.H. , Griswold D.P. Jr. : Cis-dichlorodiammine-platinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep., 63: 1459–1473, 1979.

Scanlon K.J. , Newman E.M. , Lu Y. , Priest D.G. : Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA, 83: 8923, 1986.

Vaisman A. , Varchenko M. , Umar A. , Kunkel T.A. , Risinger J.I. , Barrett J.C. , Hamilton T. C. , Chaney S.G. : The role of hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58: 3579–3585, 1998.

Cvitkovic E. : Ongoing and unsaid on oxaliplatin: the hope. Br. J. Cancer, 77: 8–11, 1998.

Lorico A. , Toffoli G. , Boiocchi M. , Erba E. , Broggini M. , Rappa G. , D'Incalci M. : Accumulation of DNA strand breaks in cells exposed to methotrexate or n(10)-propargyl-5,8-dideazafolic acid. Cancer Res., 48: 2036–2041, 1988.

Kemeny N. , Israel K. , Niedzwiecki D. , Chapman D. , Botet J. , Minsky B. , Vinciguerra V. , Rosenbluth R. , Bosselli B. , Cochran C. : Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol., 8: 313, 1990.

Loehrer P.J. , Turner S. , Kublis P. , Hui S. , Correa J. , Ansari R. , Stephens D. , Woodburn R. , Meyer S. : A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group.trial. J. Clin. Oncol., 6: 642, 1988.

Labianca R. , Pancera G. , Cesana B. , Clerici M. , Montinari F. , Luporini G. : Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur. J. Cancer Clin. Oncol., 24: 1579–1581, 1988.

Diaz-Rubio E. , Milla A. , Jimeno J. , Belon J. , Aranda E. , DiazFaes J. , Cruz Hernandez J. , Ayuso M.L. , Alonso A. , Anton A. , Martin M. : Lack of clinical synergism between cisplatin and 5-fluorouracil in advanced colorectal cancer. Results of a randomized study. Proc. Am. Soc. Clin. Oncol., 7: 110 (abstr 423), 1988.

Lokich J.J. , Ahlgren J.D. , Cantrell J. , Heim W.J. , Wampler G.L. , Gullo J.J. , Fryer J.G. , Alt D.E. : A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. Cancer, 67: 14, 1991.

Cantrell J.E. Jr. , Hart R.D. , Taylor R.F. , Harvey J.H. Jr. : Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat. Rep., 71: 615, 1987.

Iop A. , Cartei G. , Mansutti M. , Uzzau A. , Sorrentino M. , Soro P. : Hepatic arterial infusion and systemic chemotherapy for unresectable liver metastases from colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 16: 291a (abstr 1036), 1997.

Taguchi T. : Gastrointestinal cancer and oral anticancer agents. JPN J. Cancer Chemother., 26: 284–294, 1999.

Chawla S.P. , Yap B.S. , Tenney D.M. , Bodey G. , Benjamin R.S. : Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (chip, JM9)]. Invest. New Drugs, 6: 311–317, 1988.

Park J.G. , Kramer B.S. , Lai S.L. , Goldstein L.J. , Gazdar A.F. : Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J. Natl. Cancer Inst., 82: 193–198, 1990.

Mizoguchi T. , Yamada K. , Furukawa T. , Hidaka K. , Hisatsugu T. , Shimazu H. , Tsuruo T. , Sumizawa T. , Akiyama S. : Expression of MDR1 gene in human gastric and colorectal carcinoma. J. Natl. Cancer Inst., 82: 1679–1683, 1990.

Morrow C.S. , Cowan K.H. : Glutathione S-transferases and drug resistance. Cancer Cells, 2: 15–22, 1990.

Eastman A.N. , Schulte N. , Sheibani N. : Mechanisms of resistance to platinum drugs. In: Nicolini M. : Platinum and other metal coordination compounds in cancer chemotherapy, 178–196. Martinus Nijhoff, Boston, 1988.

Diaz-Rubio E. , Sastre J. , Zaniboni A. , Labianca R. , Cortes-Funes H. , de Braud F. , Boni C. , Benavides M. , Dallavalle G. , Homerin M. : Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann. Oncol., 9: 105–108, 1998.

Extra J.M. , Marty M. , Brienza S. , Misset J.L. : Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol., 25: 13–22, 1998.

Gamelin E. , Bouil A.L. , Boisdron-Celle M. , Turcant A. , Delva R. , Cailleux A. , Krikorian A. , Brienza S. , Cvitkovic E. , Robert J. , Larra F. , Allain P. : Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891–899, 1997.

Machover D. , Diaz-Rubio E. , de Gramont A. , Schilf A. , Gastiaburu J.J. , Brienza S. , Itzhaki M. , Metzger G. , N'Daw D. , Vignoud J. , Abad A. , Francois E. , Gamelin E. , Marty M. , Sastre J. , Seitz J.F. , Ychou M. : Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistent to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95–98, 1996.

Bertheault-Cvitkovic F. , Jami A. , Ithzaki M. , Brummer P.D. , Brienza S. , Adam R. , Kunstlinger F. , Bismuth H. , Misset J.L. , Levi F. : Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 2950–2958, 1996.

de Gramont A. , Vignoud J. , Tournigand C. , Louvet C. , Andre T. , Varette C. , Raymond E. , Moreau S. , Le Bail N. , Krulik M. : Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer., 33: 214–219, 1997.

Gerard B. , Bleiberg H. , Van-Daele D. , Gil T. , Hendlisz A. , Di Leo A. , Fernez B. , Brienza S. : Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs, 9: 301–305, 1998.

Zeghari-Squalli N. , Misset J.L. , Cvitkovic E. , Goldwasser F. : Mechanism of the in vitro synergism between SN38 and oxaliplatin. Proc. Am. Assoc. Cancer Res., 38: (abstr 20), 1997.

Cvitkovic E. , Wasserman E. , Goldwasser F. , Rougier P. , Ti-gaud J.M. , Mahjoubi M. , Magherini E. , Misset J.L. : Preliminary report on an oxaliplatin (LOHP)/CPT11 phase I trial in gastrointestinal (GI) malignancies: an active combination. Proc. Am. Soc. Clin. Oncol., 16: 229 (abstr 806), 1997.

Scheithauer W. , Rosen H. , Schiessel R. , Schuller J. , Karall M. , Ernst F. , Sebesta C. , Kornek G. , Hentschel E. , Marczell A. : Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil and leucovorin. Cancer, 67: 1294, 1991.

Scheithauer W. , Kornek G.V. , Raderer M. , Valencak J. , Weinlander G. , Hejna M. , Haider K. , Kwasny W. , Depisch D. : Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J. Clin. Oncol., 17: 902–906, 1999.

Andre T. , Louvet C. , Raymond E. , Tournigand C. , de Gramont A. : Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol., 9: 1251–1253, 1998.

Schmilovich A. , Chacón R , Cóppola F. , Mickiewiecz J. , Blajman C. , Black J. , Richardet E. , Stagnaro A. , Gil Dez E. , Reale M. : Expanded access program single agent oxaliplatin in fluoropyrimidine resistant advanced colorectal cancer patients. Proc. Am. Soc. Clin. Oncol., 17: 272a (abstr 1046), 1998.

Van Kooten M. , Batagejl E. , Cavarra G. , Chacón R. , Fein L. , Gercovich G. , Giglio R. , Hannois A. , Ivulich C. , Lattman R. , Hannois A. , Ivulich C. , Lattman R. , Mora R. , Perazzo F. , Rao F. , Richardet E. , Roca E. , Rodger I. , Rosembrack C. , Reale M. , Schmilovich A. : Expanded access program polichemotherapy 5-fluorouracil + leucovorin + oxaliplatin in fluoropyrimidine resistant advanced colorectal cancer patients: preliminary report. Proc. Am. Soc. Clin. Oncol., 17: 272a (abstr 1045), 1998.

Fischel J.L. , Etienne M.C. , Formento P. , Milano G. : Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin. Cancer Res., 4: 2529–2535, 1998.

Cartei G. , Rosa Bian A. , Cendron R. : Evaluation of synergy with cisplatinum in non small cell lung cancer: interim report from a multicentric study. Proc. Am. Soc. Clin. Oncol., 7: 198 (abstr 766), 1988.

Seitz J.F. , Douillard J.Y. , Paillot B. , Gamelin E. , François E. , Conroy T. , Raoul J.L. , Brunet R. , Bertheault-Cvitkovic F. , Nasca S. , Ychou M. , Jacob J. , Smith M. , Fandi A. for the French Federation Nationale des Centres de Lutte Contre le Cancer: Tomudex (raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: a promising combination. Proc. Am. Soc. Clin. Oncol., 18: 257a (abstr 986), 1999.

Guerin-Meyer V. , Delva R. , Lortholary A. , Maillart P. , Boisdrin Celle M. , Mekranter B. , Brienza S. , Chouaki N. , Larra F. , Gamelin E. : Combination of oxaliplatin (OXA)/5-FU/FA in 5-FU refractory advanced colorectal cancer patients treated with 5-FU/FA weekly PK guided regimen. Proc. Am. Soc. Clin. Oncol., 18: 260a (abstr 1001), 1999.

Maindrault-Goebel F. , de-Gramont A. , Louvet T. , Andre T. , Carola E. , Gilles-Amar V. , Lotz J.P. , Izrael V. , Krulik M. for the GERCOR: High-dose oxaliplatin with the simplified 48h bimonthly leucovorin and 5-fluorouracil regimen in pretreated metastatic colorectal cancer (FOLFOX). Proc. Am. Soc. Clin. Oncol., 18: 265a (abstr 1017), 1999.

de-Gramont A. , Maindrault-Goebel F. , Louvet C. , Andre T. , Carola E. , Gilles-Amar V. , Mabro M. , Zrael V. , Krulik M. for the GERCOR: Evaluation of oxaliplatin dose-intensity with the bimonthly 48h leucovorin and 5-fluorouracil regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 265a (abstr 1018), 1999.

Gil-Delgado M.A. , Bastian G. , Guinet F. , Benhammouda A. , Rocher M.A. , Antoine E.C. , Coeffic D. , Bismuth H. , Khayat D. : Phase I-II trial and pharmacokinetic analysis of oxaliplatin + 5FU/leucovorin + irinotecan combination in advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 18: 285a (abstr 1093), 1999.

Janinis J. , Fountzilas G. , Skarlos D.V. , Efstathiou E. , Aravantinos G. , Papakostas P. : Second line combination chemotherapy with weekly oxaliplatin and high dose 5-fluorouracil with leucovorin in metastatic colorectal carcinoma. A Hellenic Cooperative Oncology Group Study. Proc. Am. Soc. Clin. Oncol., 18: 255a (abstr 978), 1999.

Kouroussis C. , Mavroudis D. , Giannakakis T. , Ziras N. , Athanasiadis A. , Kakolyris S. , Androulakis N. , Kalbakis K. , Agelaki S. , Souglakos J. , Sarra E. , Vardakis N. , Georgoulias V. , the Greak Cooperative Group for Lung Cancer: Biweekly oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 290a (abstr 1111), 1999.

Vassilaki M. , Tsiapara S. , Desses N. , Pavlidis T. , Parassiris V. , Linos D. : First-line chemotherapy with oxaliplatin + 5-fluorouracil + leucovorin in patients with metastatic colorectal cancer. Preliminary results of a phase II study. Proc. Am. Soc. Clin. Oncol., 18: 303a (abstr 1164), 1999.

Sun Y. , Guan Z.Z. , Jin M.L. , Shi T.Z. , Li W.L. , Zhou L.Z. , Sui G.J. , Li L.Q. , Xu L.G. , Zhang J.Q. , Song S.P. , Li R. , Xu D.F. , Li Y. , Huang F.L. , Brienza S. , Ju L.Y. : A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China. Proc. Am. Soc. Clin. Oncol., 18: 255a (abstr 979), 1999.

Roca E. , Montiel M. , Barugel M. , Rodriguez M.C. , Ballarino G. , Kotliar M. , Carraro S. : 5-FU and leucovorin (MAYO regimen) plus bimonthly oxaliplatin in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 298a (abstr 1144), 1999.

Cartei G. , Cartei F. , Giraldi T. : La terapia antiblastica endo-venosa per via infusionale cronica e per cronoinfusione nei tumori maligni. XIV Corso di Aggiornamento AIOM, pp. 391–402, OCT Ed (Trieste), 1992.

Cartei F. , Cartei G. , Giraldi T. , Interlandi G. , Meneghini G. , Imperato A. , Vigevani E. , Tabaro G. : A phase II study of fluorouracil for gastrointestinal cancer. Anti-Cancer Drugs, 7: 48–53, 1996.

Cartei G. , Cartei F. , Interlandi G. : Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am. J. Clin. Oncol., 10: 57–62, 1999.

Dogliotti L. , Tampellini M. : Cronochemioterapia dei tumori del colon-retto avanzati. In: Bumma C. , Airoldi M. : Argomenti di Oncologia, vol. 1, 189–196. Archimedica Editori in Torino, Torino, 1998.

Lévi F. , Perpoint B. , Garufi C. , Focan C. , Chollet P. , Depres-Brummer P. , Zidani R. , Brienza S. , Itzhaki M. , Iacobelli S. : Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29: 1280–1284, 1993.

Lévi F. , Misset J.L. , Brienza S. , Adam R. , Metzger G. , Itzakhi M. , Caussanel J.P. , Kunstlinger F. , Lecouturier S. , Descorps-Declere A. : A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69: 893–900, 1992.

Giacchetti S. , Zidani R. , Perpoint B. , Lellouch J. , Misset J.L. , Levi F. : Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 229a (abstr 805), 1997.

Mormont M.C. , Giacchetti S. , Waterhouse J. , Lellouch J. , Misset J.L. , Levi F. : Activity circadian rhythm as an independent prognostic factor of survival in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 17: 268a (abstr 1032), 1998.

Lévi F. , Zidani R. , Giacchetti S. , Llory J.F. , Dogliotti L. , Perpoint B. , Chollet P. , Focan C. : First line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin against metastatic colorectal cancer: relationship between chronotherapy, dose intensity, response and survi val. Proc. Am. Soc. Clin. Oncol., 17: 272a (abstr 1044), 1998.